Skip to main content

SIGNIFICANT ITCH RELIEF

  • Mean ISS7 at baseline: DUPIXENT 16.25 (SD, 3.90); placebo: 15.74 (SD, 4.11)
CUPID-C
48%

vs 33% reductiona in ISS7 at Week 24
(DUPIXENT: -8.50 vs placebo: -6.13; P=0.0270, primary endpoint)1,2

  • 37% vs 28% reductiona in ISS7 at Week 12 (DUPIXENT: -6.98 vs placebo: -5.34, secondary endpoint; not significant)2
  • Mean ISS7 at baseline: DUPIXENT (n=73): 15.18 (SD, 3.59); placebo (n=75): 14.96 (SD, 3.94)1,2

In CUPID-C, definitive conclusions cannot be made for Week 12 as the analysis was not multiplicity controlled.

IN POST HOC POOLED ANALYSES OF CUPID-A AND CUPID-C, IMPROVEMENT IN ISS7:

At Week 24 was consistent regardless of patients’ baseline IgE1,2

At Week 24 was generally consistent regardless of baseline BMI2,b

Was observed as early as Week 32

  • 32% vs 23% reduction from baseline, respectively

Definitive conclusions cannot be made as these were post hoc analyses which were not multiplicity controlled.

aLSM change from baseline.

bAcross BMI stratifications: BMI (kg/m2) <25, ≥25 to <30, and ≥30.

BMI, body mass index; HSS7, hives severity score over 7 days; ISS7, itch severity score over 7 days; LSM, least squares mean; SD, standard deviation.

Explore more data
VIEW STUDY DESIGNS VIEW HSS7 EFFICACY RESULTS

Itch severity score (ISS) is a patient-reported assessment rated on a scale of 0 (none), 1 (mild itch), 2 (moderate itch), and 3 (intense itch). ISS7 is the sum of the preceding 7 days’ itch scores, for a total ISS7 range of 0 to 21.2

0 None
None
1 Mild
Present but not annoying or troublesome
2 Moderate
Troublesome but does not interfere with normal daily activity or sleep
3 Intense
Interferes with normal daily activity or sleep

SEE WHICH PATIENTS WITH CSU MAY BE APPROPRIATE FOR DUPIXENT

IDENTIFY PATIENTS